Home / Biosimilars / News

News

Momenta gains approval to start biosimilar adalimumab trial in Europe

US-based biotechnology firm Momenta Pharmaceuticals (Momenta) announced on 1 December 2014 the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a clinical trial application to initiate a clinical trial for its adalimumab biosimilar, M923.

Stada to in-license adalimumab biosimilar

German generics giant Stada Arzneimittel (Stada) announced on 18 November 2014 that it was in negotiations to in-licensing an adalimumab biosimilar.

Biosimilar infliximab launched in Japan

Japanese pharma firm Nippon Kayaku announced on 28 November 2014 the launch of its infliximab biosimilar, Infliximab BS, in Japan.

Amgen expands biosimilars programme

Biologicals major Amgen is expanding its biosimilars portfolio to include nine different molecules.

Amgen launches biosimilars info app

Biologicals major Amgen has launched an app which aims to provide a source of information about biosimilars.

Amgen sues Sandoz over filgrastim biosimilar

Biologicals major Amgen is suing Sandoz to stop the biosimilars maker from marketing a biosimilar of its top-selling product Neupogen (filgrastim) in the US. Amgen claims in its lawsuit that Sandoz did not follow the rules for biosimilar development.

Study into switching from Aranesp to biosimilar epoetin alfa

Biologicals major Amgen has started recruiting patients for a clinical trial to study the effect of switching patients from the originator biological Aranesp (darbepoetin alfa) to biosimilar epoetin alfa, in other words, from a long-acting to a short-acting epoetin.

Coherus sells shares to raise funds for biosimilars programme

US-based biosimilars developer Coherus BioSciences (Coherus) is looking for further funding for its biosimilar programme. The company is preparing to sell shares in the company in order to raise funds to get three of the biosimilars in its pipeline through clinical trials.

Stada in-licenses teriparatide biosimilar

German generics giant Stada Arzneimittel (Stada) announced on 13 October 2014 that it had made a deal to in-licensing a teriparatide biosimilar.

LG Life Sciences and Mochida make deal for adalimumab biosimilar

South Korea-based LG Life Sciences and Japan-based Mochida Pharmaceutical (Mochida) announced on 15 October 2014 that they had signed a deal to co-develop and commercialize an adalimumab biosimilar for the Japanese market.

Generics News Research General

more

Biosimilars News Research General

more